Cited by 1,392Pharmacology and Obesity TreatmentCannabis and Cannabinoid ResearchAdipokines, Inflammation, and Metabolic Diseases

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Open access

Després, Jean-Pierre, Golay, Alain, Sjöström, Lars·2005·New England Journal of Medicine

DOI 10.1056/nejmoa044537

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 months in addition to a hypocaloric diet. RESULTS: The rates of completion of the study were 62.6 percent, 60.3 percent, and 63.9 percent in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, respectively. The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea. As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P<0.001) mean weight loss (repeated-measures method, -6.7+/-0.5 kg, and last-observation-carried-forward analyses, -5.4+/-0.4 kg), reduction in waist circumference (repeated-measures method, -5.8+/-0.5 cm, and last-observation-carried-forward analyses, -4.7+/-0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0+/-1.6 percent, and last-observation-carried-forward analyses, +8.1+/-1.5 percent), and reduction in triglycerides (repeated-measures method, -13.0+/-3.5 percent, and last-observation-carried-forward analyses, -12.4+/-3.2 percent). Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone. CONCLUSIONS: Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.

Integrity signals

Registry

Crossref · 10.1056/nejmoa044537

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J. B., Ferrannini, E., & Stern, M. P. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,400
Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,782
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511

Flagged first, then by citations

Show all 38 references

1 of the 38 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

10.2337/diabetes.46.10.1594 · DOI

Sorted by citations

Items 401–500 of 999

Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease
Shah, P. K. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl392 · Cited by 51
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant
Rubio, M. Á., Gargallo, M., Millán, A. I. J., & Moreno, B. (2007) · Public Health Nutrition · doi:10.1017/s1368980007000717 · Cited by 52
The cannabinoid receptor‐1 antagonist rimonabant inhibits platelet activation and reduces pro‐inflammatory chemokines and leukocytes in Zucker rats
Schäfer, A., Pfrang, J., Neumüller, J., Fiedler, S., Ertl, G., & Bauersachs, J. K. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.158 · Cited by 52
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 52
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review
Neovius, M., & Narbro, K. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.189 · Cited by 52
Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral‐Antagonist/Inverse‐Agonist Therapies
Ward, S. J., & Raffa, R. B. (2011) · Obesity · doi:10.1038/oby.2011.69 · Cited by 50
Efficacy of rimonabant in obese patients with binge eating disorder
Pataky, Z., Gasteyger, C., Ziegler, O., Rissanen, A., Hanotin, C., & Golay, A. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1329957 · Cited by 56
Self-citation
Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide)
Hanlon, E. C. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104471 · Cited by 51
A possible role for the endocannabinoid system in the neurobiology of depression
Serra, G., & Fratta, W. (2007) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-3-25 · Cited by 51
Adiponectin multimers in maternal plasma
Mazaki‐Tovi, S., Romero, R. J., Kusanovic, J. P., Erez, O., Vaisbuch, E., Gotsch, F., Mittal, P., Than, N. G., Nhan-Chang, C. L., Chaiworapongsa, T., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802266881 · Cited by 53
Long-term effects of weight-reducing drugs in hypertensive patients
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub3 · Cited by 51
Biological specificity of visceral adipose tissue and therapeutic intervention
Perrini, S., Leonardini, A., Laviola, L., & Giorgino, F. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802334752 · Cited by 50
Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus
Karcz, W. K., Krawczykowski, D. R., Kuesters, S., Marjanović, G., Kulemann, B., Gröbe, H., Karcz-Socha, I., Hopt, U. T., Bukhari, W., & Grueneberger, J. M. (2010) · Journal of Obesity · doi:10.1155/2011/765473 · Cited by 50
The CB1 Antagonist Rimonabant Decreases Insulin Hypersecretion in Rat Pancreatic Islets
Getty‐Kaushik, L., Richard, A.-M. T., Deeney, J. T., Krawczyk, S. A., Shirihai, O. S., & Corkey, B. E. (2009) · Obesity · doi:10.1038/oby.2009.234 · Cited by 50
What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?
Schulz, P., Hryhorowicz, S., Rychter, A. M., Zawada, A. E., Słomski, R., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2021) · Nutrients · doi:10.3390/nu13020373 · Cited by 54
Role of the Endocannabinoid System in Energy Balance Regulation and Obesity
Cota, D. (2008) · KARGER eBooks · doi:10.1159/000115362 · Cited by 49
Quantification of anandamide and 2‐arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans
Thieme, U., Schelling, G., Hauer, D., Greif, R. T., Dame, T., Laubender, R. P., Bernhard, W. R., Thieme, D., Campolongo, P., & Theiler, L. G. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1561 · Cited by 50
The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism
Jenny, M., Schroecksnadel, S., Überall, F., & Fuchs, D. (2010) · Pharmaceuticals · doi:10.3390/ph3082647 · Cited by 50
The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction
Lim, S. Y., Davidson, S. M., Yellon, D. M., & Smith, C. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0034-2 · Cited by 49
Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet
Flamment, M., Guéguen, N., Wetterwald, C., Simard, G., Malthièry, Y., & Ducluzeau, P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00169.2009 · Cited by 54
Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease
Kashi, M., Torres, D., & Harrison, S. D. (2008) · Seminars in liver disease (Print) · doi:10.1055/s-0028-1091984 · Cited by 54
Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases
Richey, J. M., & Woolcott, O. O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0924-x · Cited by 50
In Vitro and in Vivo Evaluation of 11C-Labeled Azetidinecarboxylates for Imaging Monoacylglycerol Lipase by PET Imaging Studies
Cheng, R., Mori, W., Ma, L., Alhouayek, M., Hatori, A., Zhang, Y., Ogasawara, D., Yuan, G., Chen, Z., Zhang, X., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01400 · Cited by 50
Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression
Bassi, M. S., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00424 · Cited by 51
Cannabinoid‐1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin‐1/Mechanistic Target of Rapamycin Complex 2 and 5′Adenosine Monophosphate–Activated Protein Kinase Signaling
Liu, J., Godlewski, G., Jourdan, T., Liu, Z., Çınar, R., Xiong, K., & Kunos, G. (2018) · Hepatology · doi:10.1002/hep.30364 · Cited by 51
Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients with Type 2 Diabetes Mellitus
Hollander, P. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.11.014 · Cited by 49
Review article: the endocannabinoid system in liver disease, a potential therapeutic target
Basu, P. P., Aloysius, M. M., Shah, N. J., & Brown, R. S. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12673 · Cited by 48
The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat
Cluny, N. L., Chambers, A. P., Vemuri, K. V., Wood, J. T., Eller, L. K., Freni, C., Reimer, R. A., Makriyannis, A., & Sharkey, K. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.10.013 · Cited by 48
Bariatric surgery: techniques, outcomes and complications
Khwaja, H. A., & Bonanomi, G. (2009) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2009.10.005 · Cited by 51
A Treasure Trove of Hypothalamic Neurocircuitries Governing Body Weight Homeostasis
Vianna, C. R., & Coppari, R. (2010) · Endocrinology · doi:10.1210/en.2010-0778 · Cited by 51
Vascular Disease in the Metabolic Syndrome: Do We Need to Target the Microcirculation to Treat Large Vessel Disease?
Krentz, A. J., Clough, G. F., & Byrne, C. D. (2009) · Journal of Vascular Research · doi:10.1159/000226220 · Cited by 52
Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding
Ramírez-Orozco, R. E., García-Ruiz, R., Morales, P., Villalón, C. M., Villafán-Bernal, J. R., & Marichal‐Cancino, B. A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190118143014 · Cited by 51
Combination of Rimonabant and Donepezil Prolongs Spatial Memory Duration
Wise, L. E., Iredale, P. A., Stokes, R. J., & Lichtman, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301297 · Cited by 48
Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa
Müller, T. D., Reichwald, K., Brönner, G., Kirschner, J., Nguyen, T. T., Scherag, A., Herzog, W., Herpertz‐Dahlmann, B., Lichtner, P., Meitinger, T., et al. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-33 · Cited by 48
DIETARY THERAPY FOR OBESITY IS A FAILURE AND PHARMACOTHERAPY IS THE FUTURE: A POINT OF VIEW
Mark, A. L. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04454.x · Cited by 48
Present and future therapeutic strategies in non-alcoholic fatty liver disease
Calamita, G., & Portincasa, P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.9.1231 · Cited by 47
The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats
Díaz–Arteaga, A., Vazquez, M. J., Vázquez‐Martínez, R., Pulido, M. R., Suárez, J., Velasquez, D., López, M., Ross, R. A., de Fonseca, F. R., Bermúdez‐Silva, F. J., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01515.x · Cited by 47
Interactions Between Alcohol and the Endocannabinoid System
Kunos, G. (2020) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14306 · Cited by 50
The effects of cannabis and cannabinoids on the endocrine system
Meah, F. A., Lundholm, M. D., Emanuele, N., Amjed, H., Poku, C. A., Agrawal, L., & Emanuele, M. A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09682-w · Cited by 47
Role of postprandial hyperglycemia in cardiovascular disease
Fava, S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.6.859 · Cited by 47
Efficacy of Rimonabant and Other Cannabinoid CB1 Receptor Antagonists in Reducing Food Intake and Body Weight: Preclinical and Clinical Data
Carai, M. A. M., Colombo, G., Maccioni, P., & Gessa, G. L. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00091.x · Cited by 47
Tuning the oviduct to the anandamide tone
Schuel, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29424 · Cited by 49
Endocannabinoids regulate adipokine production and the immune balance of omental adipose tissue in human obesity
Ge, Q., Maury, E., Rycken, L., Gérard, J., Noël, L., Détry, R., Navez, B., & Brichard, S. M. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.123 · Cited by 46
Cannabinoid Discrimination and Antagonism by CB1 Neutral and Inverse Agonist Antagonists
Kangas, B. D., Delatte, M. S., Vemuri, K. V., Thakur, G. A., Nikas, S. P., Subramanian, K. V., Shukla, V. G., Makriyannis, A., & Bergman, J. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201962 · Cited by 47
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
Effect of Weight Loss on Nonalcoholic Fatty Liver Disease
Patel, A. A., Torres, D. M., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181b57475 · Cited by 46
From individual risk factors and the metabolic syndrome to global cardiometabolic risk
Després, J., Poirier, P., Bergeron, J., Tremblay, A., Lemieux, I., & Alméras, N. (2008) · European Heart Journal Supplements · doi:10.1093/eurheartj/sum041 · Cited by 49
Self-citation
Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages
Lanuti, M., Talamonti, E., Maccarrone, M., & Chiurchiù, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126839 · Cited by 45
The role of endocannabinoids system in fatty liver disease and therapeutic potentials
Alswat, K. (2013) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.114505 · Cited by 45
The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats
Sink, K. S., Segovia, K. N., Collins, L. E., Markus, E. J., Vemuri, K. V., Makriyannis, A., & Salamone, J. D. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.011 · Cited by 44
Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts
Kim, J. J., Carlson, M. E., & Watkins, B. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00100 · Cited by 45
The cannabinoid WIN55,212-2 protects against oxidized LDL-induced inflammatory response in murine macrophages
Hao, M., Jiang, L.-S., Fang, N., Pu, J., Hu, L., Shen, L., Song, W., & He, B. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001511 · Cited by 45
Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits
Ok, D., Ko, K., & Bae, J. Y. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0852-z · Cited by 45
The Adipose Tissue as an Endocrine Organ – A Nephrologists’ Perspective
Chudek, J. T., Adamczak, M., Nieszporek, T., & Więcek, A. (2006) · KARGER eBooks · doi:10.1159/000095320 · Cited by 46
Early identification and treatment of insulin resistance: Impact on subsequent prediabetes and type 2 diabetes
Fonseca, V. A. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80017-2 · Cited by 44
Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans
Bordicchia, M., Battistoni, I., Mancinelli, L., Giannini, E., Refi, G., Minardi, D., Muzzonigro, G., Roberta Mazzucchelli, A., Montironi, R., Piscitelli, F., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.018 · Cited by 45
Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients
Sarzani, R., Bordicchia, M., Marcucci, P., Bedetta, S., Santini, S., Giovagnoli, A., Scappini, L., Minardi, D., Muzzonigro, G., Dessı̀-Fulgheri, P., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.009 · Cited by 46
A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
Persson, U., Willis, M. S., & Ödegaard, K. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0166-1 · Cited by 44
Cannabinoid receptor 1 promotes hepatic lipid accumulation and lipotoxicity through the induction of SREBP-1c expression in zebrafish
Pai, W.-Y., Hsu, C.-C., Lai, C., Chang, T.-Z., Tsai, Y., & Her, G. M. (2013) · Transgenic Research · doi:10.1007/s11248-012-9685-0 · Cited by 46
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
Butler, H. L., & Korbonits, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0511 · Cited by 46
Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes
Jourdan, T., Szanda, G., Çınar, R., Godlewski, G., Holovac, D. J., Park, J. K., Nicoloro, S. M. C., Shen, Y., Liu, J., Rosenberg, A. Z., et al. (2017) · Diabetes · doi:10.2337/db16-1199 · Cited by 45
Ghrelin and liver disease
Quiñones, M., Fernø, J., & Al–Massadi, O. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09528-6 · Cited by 46
Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice
Quarta, C., & Cota, D. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0577-8 · Cited by 46
Metabolic syndrome and stroke
Towfighi, A., & Ovbiagele, B. I. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0008-z · Cited by 44
Rimonabant for the treatment of overweight and obese people
Burch, J., McKenna, C., Palmer, S., Norman, G., Glanville, J., Sculpher, M. J., & Woolacott, N. F. (2009) · Health Technology Assessment · doi:10.3310/hta13suppl3-03 · Cited by 44
Rimonabant: endocannabinoid inhibition for the metabolic syndrome
Wierzbicki, A. S. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01210.x · Cited by 43
Androgens, Obesity, and Sleep-Disordered Breathing in Men
Liu, P. Y., Caterson, I. D., Grunstein, R. R., & Handelsman, D. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.002 · Cited by 43
Do we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 45
Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Robinson, J. D., Cinciripini, P. M., Karam‐Hage, M., Aubin, H., Dale, L. C., NIAURA, R. S., Anthenelli, R. M., & the STRATUS Group (2017) · Addiction Biology · doi:10.1111/adb.12508 · Cited by 43
Vitamin D mitigates diabetes-associated metabolic and cognitive dysfunction by modulating gut microbiota and colonic cannabinoid receptor 1
Hussein, H. M., El-Yamany, M. F., Rashed, L. A., & Sallam, N. A. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106105 · Cited by 45
Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
Badimón, J. J., Santos‐Gallego, C. G., & Badimón, L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70150-0 · Cited by 45
Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats
Kunz, I., Meier, M. K., Bourson, A., Fisseha, M., & Schilling, W. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.3 · Cited by 43
Role of the Endocannabinoid System in Metabolic Control Processes and in the Pathogenesis of Metabolic Syndrome: An Update
Dörnyei, G., Vass, Z., Juhàsz, C., Nádasy, G. L., Hunyady, L., & Szekeres, M. (2023) · Biomedicines · doi:10.3390/biomedicines11020306 · Cited by 44
Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats
Gessa, G. L., Orrù, A., Lai, P., Maccioni, P., Lecca, R., Lobina, C., Carai, M. A. M., & Colombo, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0327-1 · Cited by 42
Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox
Dao, M., & François, H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720734 · Cited by 49
Obesity in neurobiology
Knecht, S., Ellger, T., & Levine, J. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.09.003 · Cited by 45
No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents
Müller, T. D., Reichwald, K., Wermter, A., Brönner, G., Nguyen, T. T., Friedel, S., Koberwitz, K., Engeli, S., Lichtner, P., Meitinger, T., et al. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.01.002 · Cited by 42
Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients
Lafontan, M., Piazza, P. V., & Girard, J. R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.001 · Cited by 43
CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats
Herling, A. W., Gossel, M., Haschke, G., Stengelin, S., Kuhlmann, J., Müller, G. A., Schmoll, D., & Kramer, W. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00264.2007 · Cited by 42
Peripheral modulation of the endocannabinoid system in metabolic disease
Shrestha, N., Cuffe, J. S. M., Hutchinson, D. S., Headrick, J. P., Perkins, A. V., McAinch, A. J., & Hryciw, D. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.029 · Cited by 43
The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
Scherma, M., Fadda, P., Foll, B. L., Forget, B., Fratta, W., Goldberg, S. R., & Tanda, G. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927859 · Cited by 43
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice
Migrenne, S., Lacombe, A., Lefèvre, A.-L., Pruniaux, M., Guillot, E., Galzin, A., & Magnan, C. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90824.2008 · Cited by 42
The relation of adipose tissue to cardiometabolic risk
Pi-Sunyer, X. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80040-2 · Cited by 41
Emerging Strategies for Increasing High-Density Lipoprotein
Forrester, J. S., & Shah, P. K. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.06.059 · Cited by 44
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review
Alsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 42
A Myriad of Pathways to NASH
Larrain, S., & Rinella, M. E. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.009 · Cited by 40
Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial
Andries, A., Frystyk, J., Flyvbjerg, A., & Støving, R. K. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.07.006 · Cited by 40
Metabolic aspects of obstructive sleep apnoea syndrome
Bonsignore, M. R., & Eckel, J. (2009) · European Respiratory Review · doi:10.1183/09059180.00000109 · Cited by 39
Cannabinoids in the Cardiovascular System
Ho, W. ‐. V., & Kelly, M. E. M. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.05.002 · Cited by 40
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice
Han, J. H., Shin, H., Park, J.-Y., Rho, J. G., Son, D. H., Kim, K. W., Seong, J. K., Yoon, S.-H., & Kim, W. (2018) · The FASEB Journal · doi:10.1096/fj.201801152rr · Cited by 41
Cannabinoid receptor 1 disturbance of PPARγ2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli
Lin, C., Hsu, Y., Lee, P., Lei, C., Wang, J., Huang, Y., Wang, S.-Y., & Wang, F. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1125-6 · Cited by 42
Involvement of hypothalamic peptides in the anorectic action of the CB1 receptor antagonist rimonabant (SR 141716)
Verty, A. N. A., Boon, W. M., Mallet, P. E., McGregor, I. S., & Oldfield, B. J. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06750.x · Cited by 39
Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats
Järbe, T. U. C., LeMay, B. J., Olszewska, T., Vemuri, K. V., WOOD, J., & Makriyannis, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.06.014 · Cited by 39
Medical Treatment of Non-alcoholic Steatohepatitis
Kadayıfçı, A., Merriman, R. B., & Bass, N. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.001 · Cited by 38
Therapeutic Options for Modifying Cardiometabolic Risk Factors
Aronne, L. J. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.01.005 · Cited by 39
The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome
Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A. I., & Athyros, V. G. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007299358 · Cited by 39
The market in diabetes
Hauber, A., & Gale, E. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0108-0 · Cited by 39
The ‘valvulo-metabolic’ risk in calcific aortic valve disease
Mathieu, P., Després, J., & Pîbarot, P. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)71008-5 · Cited by 39
Self-citation
Activation of Cannabinoid Receptor Type 1 (Cb1r) Disrupts Hepatic Insulin Receptor Signaling via Cyclic AMP-response Element-binding Protein H (Crebh)-mediated Induction of Lipin1 Gene
Chanda, D., Kim, Y., Kim, D., Lee, M., Lee, S.-Y., Park, T., Koo, S., Lee, C., & Choi, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377978 · Cited by 38
Maternal high-fat diet consumption induces sex-dependent alterations of the endocannabinoid system and redox homeostasis in liver of adult rat offspring
Miranda, R. A., de Almeida, M. M., Dias-Rocha, C. P., Fassarella, L. B., Souza, L. L., Souza, A. F. P., de Andrade, C. B. V., Fortunato, R. S., Pazos-Moura, C. C., & Trevenzoli, I. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-32906-0 · Cited by 38

Authors: Després, J.-P., Golay, A., & Sjöström, L.
Affiliations: Université Laval (CA)
University Hospital of Geneva (CH)
Sahlgrenska University Hospital (SE)
ORCID: Després, Jean-Pierre
Golay, Alain
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-11-17
Volume: 353
Issue: 20
Pages: 2121-2134
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa044537
OpenAlex: W2087587748
Cited by: 1,392
References: 38
Citations by year: 2026: 17 · 2025: 19 · 2024: 18 · 2023: 26 · 2022: 20 · 2021: 28 · 2020: 27 · 2019: 26 · 2018: 32 · 2017: 24 · 2016: 25 · 2015: 34 · 2014: 31 · 2013: 53 · 2012: 63
FWCI: 138.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords: rimonabant, cannabinoid-1 receptor antagonist, dyslipidemia, overweight, obesity, weight loss, adiponectin, HDL cholesterol, triglycerides, waist circumference, hypocaloric diet, cardiovascular risk factors, dose comparison, body mass index, lipid-lowering therapy
MeSH terms: Rimonabant, Adult, Aged, Blood Glucose, Cholesterol, Double-Blind Method, Female, Humans, Insulin, Male, Middle Aged, Obesity, Piperidines, Pyrazoles, Risk Factors, Triglycerides, Weight Loss, Anti-Obesity Agents, Leptin, Metabolic Syndrome, Dyslipidemias, Overweight, Adiponectin, Cannabinoid Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks